当前位置： SCI文献检索 > ANNALS OF THE RHEUMATIC DISEASES期刊下所有文献 > Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus.

Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus.

Abstract：

OBJECTIVES:To study the prevalence of remission and its effect on damage and quality of life (QOL) in Chinese patients with systemic lupus erythematosus (SLE). METHODS:Patients who fulfilled ≥4 American College of Rheumatology criteria for SLE were identified. Their remission status at last clinic visits was determined by the European consensus criteria (complete/clinical remission ± immunosuppressive drugs). The increase in SLE damage index (SDI) in the preceding 5 years was compared between patients who were and were not in remission for ≥5 years. QOL of patients as assessed by the validated Chinese version of the Medical Outcomes Study Short-Form-36 (SF36) and the LupusPRO was also compared between the remission and non-remission groups by statistical analysis. RESULTS:769 SLE patients were studied (92% women; age: 46.4±14.6 years; SLE duration: 12.6±8.1 years). At last visit, clinical remission was present in 259 (33.7%) patients and complete remission was present in 280 (36.4%) patients. Clinical and complete remissions for ≥5 years were achieved in 64 (8.3%) and 129 (16.8%) of the patients, respectively. Patients remitted for ≥5 years were older, and had significantly lower prevalence of renal involvement, leucopenia or thrombocytopaenia. Fifty-three (6.9%) patients in remission ≥5 years were taken off all medications, including hydroxychloroquine (HCQ) (drug-free). Patients who remitted for ≥5 years but off-therapy (except HCQ) had significantly less SDI increment than those who did not remit (0.17±0.53 vs 0.67±1.10; p<0.001). Among 453 patients who had QOL assessment, remission for ≥5 years was associated with significantly higher SF36 and the total health-related scores of the LupusPRO. CONCLUSIONS:Durable remission can be achieved in a quarter of patients with SLE. Patients with remission for ≥5 years have significantly less damage accrual and better QOL. Prolonged remission is an appropriate criterion for outcome assessment in SLE.

journal_name

Ann Rheum Dis

journal_title

Annals of the rheumatic diseases

authors

Mok CC,Ho LY,Tse SM,Chan KL

doi

10.1136/annrheumdis-2016-210382

subject

Has Abstract

pub_date

2017-08-01 00:00:00

pages

1420-1425

issue

eissn

0003-4967

issn

1468-2060

pii

annrheumdis-2016-210382

journal_volume

pub_type

杂志文章

在线工具

Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus.